Download PDF
Thromb Haemost 1992; 68(02): 214-220
DOI: 10.1055/s-0038-1656351
Original Article
Schattauer GmbH Stuttgart

Ridogrel Inhibits Systemic and Renal Formation of Thromboxane A2 and Antagonizes Platelet Thromboxane A2/Prostaglandin Endoperoxide Receptors upon Chronic Administration to Man

C Weber
4   The Janssen Research Foundation, Neuss (Rosellen), Germany
,
J R Beetens
1   The Department of Cardiovascular Pharmacology, Janssen Research Foundation, Beerse, Belgium
,
F Tegtmeier
4   The Janssen Research Foundation, Neuss (Rosellen), Germany
,
P Van Rooy
2   The Clinical Pharmacology, Janssen Research Foundation, Beerse, Belgium
,
E Vercammen
3   The Clinical R & D, Janssen Research Foundation, Beerse, Belgium
,
L Wouters
1   The Department of Cardiovascular Pharmacology, Janssen Research Foundation, Beerse, Belgium
,
F De Clerck
1   The Department of Cardiovascular Pharmacology, Janssen Research Foundation, Beerse, Belgium
› Author Affiliations
Further Information

Publication History

Received 08 October 1991

Accepted after revision 25 March 1992

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The effects of ridogrel, a dual thromboxane A2 (TXA2) synthase inhibitor and TXA2/prostaglandin (PG) endoperoxide receptor antagonist, on systemic and renal production of prostaglandins and on platelet TXA2/PG endoperoxide receptors was evaluated upon chronic administration (300 mg b. i. d. orally, for 8 and 29 days) to man. Such a medication with ridogrel inhibits the systemic as well as the renal production of TXA2 as measured by the urinary excretion of 2,3-dinor-TXB2 and TXB2 respectively without inducing significant changes in systemic or renal PGI2 production. Simultaneously with the latter effects, the production of TXB2 by spontaneously coagulated whole blood ex vivo is inhibited (>99%) while that of PGE2 and PGF2α is largely increased. Administration of ridogrel causes a three- to five-fold shift to the right of concentration-response curves for U46619 in eliciting platelet aggregation; no tachyphylaxis is observed after 29 days of treatment in this respect. Apart from a reduction of serum uric acid levels with a concomitant increase in urinary uric acid excretion during the first days of treatment, no clinically significant changes in hematological, biochemical, hemodynamic and coagulation parameters occur during the 8 days or 29 days study. The study demonstrates that ridogrel is a potent inhibitor of the systemic as well as renal TXA2 synthase and an antagonist of platelet TXA2/PG endoperoxide receptor in man, covering full activity during 24 h at steady-state plasma level conditions without tachyphylaxis during 29 days of medication. The compound is well tolerated, at least during 1 month of administration.

 

  • References

  • 1 Moncada S, Vane JR. Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 1978; 34: 129-135
    CrossrefPubMedGoogle Scholar
  • 2 Reilly IAG, Doran JB, Smith B, Fitzgerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986; 73: 1300-1309
    CrossrefPubMedGoogle Scholar
  • 3 Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989
    CrossrefPubMedGoogle Scholar
  • 4 Fitzgerald DJ, Wright F, Fitzgerald GA. Increased thromboxane biosynthesis during coronary thrombolysis: evidence that platelet activation and thromboxane A2 modulate the respone to tissue-type plasminogen activator. Circ Res 1989; 65: 83-94
    CrossrefPubMedGoogle Scholar
  • 5 Fitzgerald DJ, Rocki W, Murray R, Mayo G, Fitzgerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990; 335: 751-754
    CrossrefPubMedGoogle Scholar
  • 6 Golino P, Buja LM, Ashton JM, Kulkarni P, Taylor A, Willerson JT. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed arteries. Circulation 1988; 78: 701-711
    CrossrefPubMedGoogle Scholar
  • 7 Golino P, Rosolowsky M, Yao S, McNatt J, De Clerck F, Buja LM, Willerson JT. Blockade of TXA2 receptors and inhibition of TXA2 synthase enhances thrombolysis and prevents reocclusion more efficiently than either intervention alone. J Clin Invest 1990; 86: 1095-102
    CrossrefPubMedGoogle Scholar
  • 8 Patrono C, Ciabattoni G, Remuzzi G, Gotti E, Bombardieri S, Di Munno O, Tartarelli G, Cinotti GA, Simonetti BM, Pierucci A. Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. J Clin Invest 1985; 76: 1011-1018
    CrossrefPubMedGoogle Scholar
  • 9 Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1-12
    CrossrefPubMedGoogle Scholar
  • 10 Niwa T, Maeda K, Shibata M, Yamada K. Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome. Clin Nephrol 1988; 30: 276-281
    PubMedGoogle Scholar
  • 11 Lote CJ, Haylor J. Eicosanoids in renal function. Prostaglandins, Leukotrienes, Ess Fatty Acids 1989; 36: 203-217
    PubMedGoogle Scholar
  • 12 Vermylen J, Carreras LO, Van Schaeren J, De Freyn G, Machin SJ, Verstraete M. Thromboxane synthetase inhibition as anti-thrombotic strategy. Lancet 1981; i: 1073-1075
    PubMedGoogle Scholar
  • 13 De Freyn G, Deckmyn H, Vermylen J. A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2 . Thromb Res 1982; 26: 389-400
    CrossrefPubMedGoogle Scholar
  • 14 Fitzgerald GA, Reilly IAG, Pedersen AK. The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation 1985; 72: 1194-201
    CrossrefPubMedGoogle Scholar
  • 15 De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen PAJ. R 68070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-42
    PubMedGoogle Scholar
  • 16 De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PAJ. R 68070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule. II. Pharmacological effects in vivo and ex vivo. Thromb Haemostas 1989; 61: 43-49
    PubMedGoogle Scholar
  • 17 Nowak J, Fitzgerald GA. Redirection of prostaglandin endoperoxide metabolism at the platelet vascular interface in man. J Clin Invest 1989; 83: 380-385
    CrossrefPubMedGoogle Scholar
  • 18 Gresele P, Arnout J, Deckmyn H, Vermylen J. Thromboxane synthetase inhibition combined with thromboxane receptor blockade: a step forward in antithrombotic strategy?. Thromb Haemostas 1984; 52: 634
    PubMedGoogle Scholar
  • 19 Gresele P, Arnout J, Deckmyn H, Vermylen J. Endogenous antiaggregatory prostaglandins can contribute to inhibition of hemostasis: a pharmacological study in vivo in humans. Adv Raven Press; New York: 1987: 248-253
    Google Scholar
  • 20 Fitzgerald DJ, Fragetta J, Fenelon LC, Fitzgerald GA. Thromboxane synthase inhibition and thromboxane/endoperoxide receptor antagonism in a chronic canine model of coronary thrombosis. Adv Raven Press; New York: 1987: 496-500
    Google Scholar
  • 21 Vandeplassche G, Hermans C, Van de Water A, Xhonneux R, Wouters L, Van Ammel K, De Clerck F. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries. Circ Res 1991; 69: 313-324
    CrossrefPubMedGoogle Scholar
  • 22 Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J. R 68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 1990; 75: 646-653
    PubMedGoogle Scholar
  • 23 Weber C, Höller M, Beetens J, De Clerck F, Tegtmeier F. Quantitative determination of 2,3-dinor-TXB2, 2,3-dinor-6-keto-PGFlα TXB2, 6-keto-PGFlα, PGE2, PGD2 and PGF2α in human urine by GC-NiCi-MS. J Chromatogr Biomed Appl 1991; 562: 599-611
    CrossrefPubMedGoogle Scholar
  • 24 Weber C, Belsner K, Lohkamp R, Höller M. Determination of prostaglandins D2, E2, F2α and 6-keto-prostaglandin Flα as well as thromboxane B2 in rat brain by gas chromatography mass spectrometry. J Chromatogr Biomed Appl 1988; 426: 345-350
    CrossrefPubMedGoogle Scholar
  • 25 Beetens JR, Van den Bossche R, Herman AG. Production of 6-oxo-PGFlα by aorta rings in the presence of ascorbic acid. Arch Int Pharmacodyn Ther 1982; 256: 151-152
    PubMedGoogle Scholar
  • 26 Weber C, Beetens JR, Van de Wiele R, Höller M, De Clerck F. Production of thromboxane and prostaglandins in human blood in the presence of thromboxane synthase inhibitors: a comparison of RIA and GC/MS determinations. Blood Coag Fibr 1991; 2: 7-13
    PubMedGoogle Scholar
  • 27 Kroll MH, Chesler R, Hagengruber C, Blank DW, Kestner J, Rawe M. Automated determination of urinary creatinine without sample dilution: theory and practice. Clin Chem 1986; 32: 446-452
    PubMedGoogle Scholar
  • 28 Milliken GA, Johnson DE. (eds). Analysis of Messy Data. Wadsworth Inc., Belmont, CA 1984; pp473P
    PubMed
  • 29 Roberts LJ, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identification of twenty urinary metabolites. J Biol Chem 1981; 256: 8384-8393
    PubMedGoogle Scholar
  • 30 Catella F, Fitzgerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res 1987; 47: 647-656
    CrossrefPubMedGoogle Scholar
  • 31 Patrono C. Measurement of thromboxane biosynthesis in man. Eicosanoids 1989; 2: 249-251
    PubMedGoogle Scholar
  • 32 Fitzgerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
    CrossrefPubMedGoogle Scholar
  • 33 Barrow SE, Ward PS, Sleightholm MA, Ritter JM, Dollery CT. Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim Biophys Acta 1989; 993: 121-127
    CrossrefPubMedGoogle Scholar
  • 34 Chiabrando C, Pinciroli V, Campoleoni A, Benighi A, Picinelli A, Fanelli R. Quantitative profiling of 6-keto-prostaglandin Flα, 2,3-dinor-6-keto-prostaglandin Flα, thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine by immunoaffinity extraction with gas chromatography mass spectrometry. J Chromatogr Biomed Appl 1989; 495: 1-11
    CrossrefPubMedGoogle Scholar
  • 35 Falardeau P, Oates JA, Brash AR. Quantitative analysis of two dinor urinary metabolites of prostaglandin I2 . Anal Biochem 1981; 115: 359-367
    CrossrefPubMedGoogle Scholar
  • 36 Fisher S, Bernutz C, Meier H, Weber PC. Formation of prostacyclin and thromboxane in man as measured by the main urinary metabolites. Biochem Biophys Acta 1986; 876: 194-199
    CrossrefPubMedGoogle Scholar
  • 37 Lorenz RL, Fisher S, Wober W, Wagner HA, Weber PC. Effects on prostanoid formation and pharmacokinetics of Dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor in man. Biochem Pharmacol 1986; 35: 761-766
    CrossrefPubMedGoogle Scholar
  • 38 Mohrland JS, Vander LugtJT, Gorman RR, Lakings DB. Thromboxane synthase activity and platelet function after furegrelate administration in man. J Clin Pharmacol 1989; 29: 53-58
    CrossrefPubMedGoogle Scholar
  • 39 Reilly IAG, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
    PubMedGoogle Scholar
  • 40 Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. J Pharmacol Exp Ther 1984; 228: 472-477
    PubMedGoogle Scholar
  • 41 Zipser RD. Effects of selective inhibition of thromboxane synthesis on renal functions in humans. Am J Physiol (Renal fluid and electrolyte physiology) 1985; 17: F753-F756
    PubMedGoogle Scholar
  • 42 Zipser RD, Kronborg I, Rector W, Reynolds T, Daskalopoulos G. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 1984; 87: 1228-1232
    PubMedGoogle Scholar
  • 43 Fitzgerald GA, Brash AR, Oates JA, Pedersen AK. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 71: 1336-1343
    CrossrefPubMedGoogle Scholar
  • 44 Fitzgerald GA, Oates JA. Selective and non-selective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35: 633-640
    CrossrefPubMedGoogle Scholar
  • 45 Henrikson P, Rasmanis G, Edhag O, Vesterquist O, Green K. Thromboxane synthase inhibition: “endoperoxide shunt phenomenon” does not occur in healthy humans in vivo. Prostaglandins 1990; 39: 99-107
    CrossrefPubMedGoogle Scholar
  • 46 Gorman RR. Biology and biochemistry of thromboxane synthetase inhibitors. Adv Raven Press; New York: 1983: 235-240
    Google Scholar
  • 47 De Clerck F, Van Gorp L, Beetens J, Verheyen A, Janssen PAJ. Arachidonic acid metabolites, ADP and thrombin modulate occlusive thrombus formation over extensive arterial injury in the rat. Blood Coag Fibr 1990; 1: 247-258
    PubMedGoogle Scholar
  • 48 Thomas M, Lumley P, Ballard P, O'Brien JR. Initial studies in man with a novel thromboxane receptor blocking drug GR32191. Thromb Haemostas 1987; 58: 181
    PubMedGoogle Scholar
  • 49 Yasuda T, Gold HK, Yaoita H, Guerrero LJ, Holt R, Fallon JT, Leinbach RC, Collen D. Effect of ridogrel, a thromboxane synthase inhibitor/endoperoxide receptor antagonist, on platelet-rich coronary arterial thrombosis in the dog. Circulation 1989; 80 (Suppl 4) 32
    PubMedGoogle Scholar
  • 50 Vesterqvist C. Measurements of the in vivo synthesis of thromboxane and prostacyclin in humans. Scand J Clin Lab Invest 1988; 48: 401-407
    CrossrefPubMedGoogle Scholar
  • 51 Edlund A, Fitzgerald GA, Sevastik B, Wennmalm A. Leg exercise increases prostacyclin synthesis without activating platelets in both healthy and atherosclerotic humans. In: Adv Prostaglandin Thromboxane Leukotriene Res., Vol. 17. Raven Press; New York: 1987: 447-449
    Google Scholar
  • 52 Frölich JC, Marx KH, Bippi H, Fauler J, Rosenkrauz B, Förstermann V. Analysis of eicosanoids by GC-MS/MS. Methodological surveys Biochemistry and analysis, Vol 18. Plenum Press; New York: 1987: 15-21
    Google Scholar
  • 53 Rapold HJ, Van de Werf F, De Geest H, Arnout J, Sangtawesin W, Vercammen E, De Clerck F, Weber C, Collen D. Pilot study of combined administration of ridogrel and alteplase in patients with acute myocardial infarction. Cor Art Dis 1991; 2: 455-463
    PubMedGoogle Scholar